17 results about "Prednisolone" patented technology

The invention belongs to the technical field of medicine detection, and particularly relates to an LCMS (Liquid Chromatography Mass Spectrometry) detection method for histamine in prednisolone. Respectively injecting the reference solution, the test solution and the blank solution into an LCMS (Liquid Chromatography Mass Spectrometer), recording a spectrogram, and calculating the content of histamine in prednisolone by adopting an external standard method; wherein the detection condition of the LCMS comprises a mobile phase, and the mobile phase adopts acetonitrile as a mobile phase A and a 10mM ammonium formate aqueous solution containing 0.1 vol% of formic acid as a mobile phase B. The method is good in reproducibility and stability and high in precision.

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

The invention relates to a preparation method of prednisone acetate. The preparation method comprises the following steps: carrying out secondary culture on arthrobacter simplex; adding a crude product of cortisone acetate into the arthrobacter simplex subjected to secondary culture, performing fermentation conversion, and performing conversion by adopting a mode of gradient temperature control and batch addition of an organic solvent to obtain a crude product of prednisone acetate; refining the prednisone acetate crude product, pulping with ethyl acetate, heating and refluxing, and repeatedly refining for multiple times to obtain a prednisone acetate refined product; and heating and dissolving the prednisone acetate refined product with ethyl acetate, adding activated carbon and water, heating and refluxing, filtering and concentrating to obtain the prednisone acetate refined product. According to the method disclosed by the invention, a mode of gradient temperature control and batch addition of the organic solvent is adopted during conversion, so that the strain conversion efficiency is improved, and the conversion rate of prednisone acetate reaches 94% or above; during refining, a pulping mode is adopted, so that the batch feeding amount is increased, a repeated refining and concentrating process is removed, the solvent consumption is reduced, and the process time is greatly shortened.

The present disclosure relates to the use of cortisol, cortisone, cortisone acetate, hydrocortisone, fludrocortisone, prednisolone, prednisone, methylprednisolone, Dehydroepiandrosterone (DHEA), dexamethasone, betamethasone, adrenocorticotropic hormone (ACTH), ganaxolone, tetracosactide or combinations thereof for preventing and / or reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The disclosure further provides pharmaceutical compositions and methods for preventing and / or reducing the risk of SUDEP, particularly in Dravet Syndrome patients.

The invention relates to the technical field of perovskite thin films, in particular to a preparation method of a fluorine-containing steroid molecule regulated perovskite thin film, the perovskite thin film and a photovoltaic device.The perovskite thin film comprises a precursor composition, the precursor composition is a perovskite precursor salt solution, and the perovskite precursor salt solution is composed of precursor salt, a solvent system and fluorine-containing steroid molecules Dex, the precursor salt is Cs0.05 (FA0.95 MA0.05) 0.95 Pb (I0.95 BT0.05) 3, the precursor salt comprises FAI, PbI2, MACl, PbBr2, CsI and MABr, the fluorine-containing steroid molecule Dex has a steroid ring rigid skeleton and simultaneously contains = O,-OH and C-F functional sites, the fluorine-containing steroid molecule Dex is preferably dexamethasone Dex, and the fluorine-containing steroid molecule Dex is replaced by prednisolone, triamcinolone acetonide and flumetasone; the solvent system is composed of DMP and NMP, the volume ratio of DMP to NMP is 4: 1, and the solvent system contains an organic solvent. The semitransparent perovskite thin film prepared by the invention has high transmittance and excellent crystallization quality, and the open-circuit voltage, the fill factor and the operation and storage stability of a prepared device are remarkably improved.

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).

The application provides a culture method and composition for prolonging the in-vitro survival time of neutrophils. The composition provided by the application comprises prednisolone and beta-mercaptoethanol, which can prolong the survival time of neutrophils. The method provided by the application has low cost, simple operation, small interference to cell function, can guarantee an experimental window of 3-4 days, and has good application value.

The invention discloses a preparation method of prednisolone, which comprises the following steps: inoculating arthrobacter simplex to a slant culture medium for preliminary culture, and then transferring the slant culture to a seed solution culture medium for enlarged culture to obtain a seed solution; transferring the seed solution into a fermentation culture medium, controlling the culture temperature to be 29-31 DEG C, culturing for 10-16 hours, adding hydrocortisone and absolute ethyl alcohol, controlling the conversion temperature to be 32-34 DEG C, and converting for 20-25 hours. The prednisolone preparation method provided by the invention has the characteristics of high fermentation conversion rate, short period and low production cost, and is very suitable for industrial production.

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone encapsulated in a liposomal carrier and methods of use thereof.

The invention provides a method for detecting the content of aflatoxin B1, B2, G1 and G2 in prednisolone through a fermentation process, which comprises the following steps: A) dissolving a sample to be detected by adopting a solvent, performing ultrasonic extraction, and filtering to obtain a liquid to be detected; b) preparing a mixed standard control solution of aflatoxin B1, B2, G1 and G2; and C) carrying out qualitative and quantitative analysis on the to-be-detected solution and the mixed standard control solution by adopting HPLC-MS / MS to obtain a detection result. According to the method disclosed by the invention, a rapid and simple pretreatment mode is combined with high performance liquid chromatography-triple quadrupole mass spectrometry, so that the aflatoxin B1, B2, G1 and G2 detection sensitivity is high, the separation degree and peak shape are good, and the detection result is reliable.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

The application discloses application of water extract of Euryale ferox in preparation of food and medicine for improving osteoporosis, and relates to the technical field of natural medicine. The raw Euryale ferox, salt-fried Euryale ferox and bran-fried Euryale ferox are respectively used as raw materials, and the water extract of Euryale ferox is prepared by using a water extraction process after standard cleaning and processing. A double pharmacodynamic evaluation system of a prednisolone-induced zebra fish skull osteoporosis in vivo model and an MC3T3-E1 cell osteogenic differentiation in vitro model is established, and the in-vivo anti-osteoporosis effect, embryonic development safety, in-vitro cytotoxicity and osteogenic differentiation activity of the water extract of Euryale ferox with different processing methods and different concentrations are systematically investigated. The salt-fried Euryale ferox has better pharmacodynamic effect than the raw Euryale ferox and the bran-fried Euryale ferox under the same concentration. The application provides a scientific basis for the application of Euryale ferox in the development of anti-osteoporosis drugs.

The invention provides application of a KRAS inhibitor combined with glucocorticoid in preparation of a medicine for treating cancers, and belongs to the technical field of biological medicines. The invention provides a combined application of a KRAS inhibitor and glucocorticoid in preparation of a medicine for treating cancers. Compared with the single use of the KRAS inhibitor or prednisolone, the combined use of the KRAS inhibitor and prednisolone can more effectively inhibit the proliferation and survival of KRAS G12C mutated NSCLC cells and slow down the growth of tumor volume. In addition, prednisolone can relieve the acquired drug resistance problem of KRASi by blocking generation of TNF and I-type IFN induced by a KRAS inhibitor, and prednisolone and prednisolone have a synergistic anti-tumor effect. The two can be directly combined for medication, can also be prepared into a combined agent for treating cancers, and has a good clinical transformation prospect.

The invention relates to a compound of formula:which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

This invention discloses a quantitative analysis method for the blood concentrations of HYQ-169 and prednisolone and its application, belonging to the fields of medical testing and pharmaceutical analysis. The quantitative analysis method includes the following steps: preparing standard curve samples and quality control samples; adding internal standard solution; extracting with ethyl acetate; drying the supernatant and reconstituteing; separating using SPE; drying the fraction and reconstituteing again; detecting using UPLC-MS / MS; establishing a standard curve and obtaining a regression equation; adding internal standard solution to the plasma sample to be tested and processing it in the same way; calculating the blood concentrations of HYQ-169 and prednisolone according to the regression equation. This invention can simultaneously perform quantitative detection of two drug components with significantly different chemical properties in a single analysis, with high sensitivity, high accuracy, and fast analysis speed, providing a foundation for preclinical and clinical pharmacokinetic studies of HYQ-169.

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone, encapsulated in a liposomal carrier, and methods of using the same.

This invention discloses a method for simultaneously detecting cefepime and its metabolites, as well as prednisolone residues in milk. The method includes the following steps: taking a milk sample, extracting with acetonitrile, centrifuging, and collecting the supernatant; adding acetonitrile-saturated n-hexane for liquid-liquid extraction to remove fat; concentrating the extracted solution, reconstituted with phosphate buffer at pH 8.5 ± 0.2, purifying with a hydrophilic-lipophilic equilibrium solid-phase extraction column, eluting, concentrating, and reconstituted to obtain the test solution; and detecting the test solution using ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS). This invention, through optimized pretreatment processes, particularly the dual purification strategy of "n-hexane degreasing + HLB solid-phase extraction" combined with precise pH adjustment, effectively removes complex fat and protein matrix interferences in milk, significantly reducing matrix effects; combined with optimized gradient elution procedures and multiple reaction monitoring (MRM) mass spectrometry conditions, it achieves simultaneous, rapid, and highly sensitive detection of cefepime, deacetylated cefepime, and prednisolone.